149 related articles for article (PubMed ID: 10467409)
41. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions.
Mai M; Huang H; Reed C; Qian C; Smith JS; Alderete B; Jenkins R; Smith DI; Liu W
Genomics; 1998 Aug; 51(3):359-63. PubMed ID: 9721206
[TBL] [Abstract][Full Text] [Related]
42. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers.
Nomoto S; Haruki N; Kondo M; Konishi H; Takahashi T; Takahashi T; Takahashi T
Cancer Res; 1998 Apr; 58(7):1380-3. PubMed ID: 9537234
[TBL] [Abstract][Full Text] [Related]
43. Mutational and expression analysis of the p73 gene in melanoma cell lines.
Tsao H; Zhang X; Majewski P; Haluska FG
Cancer Res; 1999 Jan; 59(1):172-4. PubMed ID: 9892203
[TBL] [Abstract][Full Text] [Related]
44. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas.
Sunahara M; Ichimiya S; Nimura Y; Takada N; Sakiyama S; Sato Y; Todo S; Adachi W; Amano J; Nakagawara A
Int J Oncol; 1998 Aug; 13(2):319-23. PubMed ID: 9664127
[TBL] [Abstract][Full Text] [Related]
45. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Vikhanskaya F; D'Incalci M; Broggini M
Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
[TBL] [Abstract][Full Text] [Related]
46. Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas.
Geli J; Nord B; Frisk T; Edström Elder E; Ekström TJ; Carling T; Bäckdahl M; Larsson C
Int J Oncol; 2005 May; 26(5):1385-91. PubMed ID: 15809732
[TBL] [Abstract][Full Text] [Related]
47. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.
Corn PG; Kuerbitz SJ; van Noesel MM; Esteller M; Compitello N; Baylin SB; Herman JG
Cancer Res; 1999 Jul; 59(14):3352-6. PubMed ID: 10416592
[TBL] [Abstract][Full Text] [Related]
49. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma.
Kang MJ; Park BJ; Byun DS; Park JI; Kim HJ; Park JH; Chi SG
Clin Cancer Res; 2000 May; 6(5):1767-71. PubMed ID: 10815895
[TBL] [Abstract][Full Text] [Related]
50. p73 in apoptosis.
Stiewe T; Pützer BM
Apoptosis; 2001 Dec; 6(6):447-52. PubMed ID: 11595834
[TBL] [Abstract][Full Text] [Related]
51. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma.
Takahashi H; Ichimiya S; Nimura Y; Watanabe M; Furusato M; Wakui S; Yatani R; Aizawa S; Nakagawara A
Cancer Res; 1998 May; 58(10):2076-7. PubMed ID: 9605745
[TBL] [Abstract][Full Text] [Related]
52. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
53. Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer.
Chi SG; Chang SG; Lee SJ; Lee CH; Kim JI; Park JH
Cancer Res; 1999 Jun; 59(12):2791-3. PubMed ID: 10383132
[TBL] [Abstract][Full Text] [Related]
54. P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63?
Faridoni-Laurens L; Bosq J; Janot F; Vayssade M; Le Bihan ML; Kaghad M; Caput D; Bénard J; Ahomadegbe JC
Oncogene; 2001 Aug; 20(38):5302-12. PubMed ID: 11536043
[TBL] [Abstract][Full Text] [Related]
55. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver.
Tannapfel A; Engeland K; Weinans L; Katalinic A; Hauss J; Mössner J; Wittekind C
Br J Cancer; 1999 Jun; 80(7):1069-74. PubMed ID: 10362118
[TBL] [Abstract][Full Text] [Related]
56. Mutation and expression analysis of LZTS1 in ovarian cancer.
Arnold JM; Choong DY; Lai J; Campbell IG; Chenevix-Trench G
Cancer Lett; 2006 Feb; 233(1):151-7. PubMed ID: 15876481
[TBL] [Abstract][Full Text] [Related]
57. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
58. Expression of the vascular endothelial growth factor gene is inhibited by p73.
Salimath B; Marmé D; Finkenzeller G
Oncogene; 2000 Jul; 19(31):3470-6. PubMed ID: 10918605
[TBL] [Abstract][Full Text] [Related]
59. Chromosome 8 genetic analysis and phenotypic characterization of 21 ovarian cancer cell lines.
Arnold JM; Woollatt E; Chenevix-Trench G
Cancer Genet Cytogenet; 2002 Dec; 139(2):109-14. PubMed ID: 12550770
[TBL] [Abstract][Full Text] [Related]
60. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer.
Peters MA; Janer M; Kolb S; Jarvik GP; Ostrander EA; Stanford JL
Prostate; 2001 Sep; 48(4):292-6. PubMed ID: 11536309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
